Donna Kulas
Family · Concord, MANPI 1184736969
Payments from drug & device makers
Across 32 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$219
- UCB, Inc.$80
- Novartis$53
- Arcutis Biotherapeutics, Inc.$49
- Botanix SB Inc$36
- E.r. Squibb & Sons, L.L.C.$29
- plus $188 from 8 others
What the payments were for
- Food & beverage$654100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 15 | $219 |
| UCB, Inc. | 2 | $80 |
| Novartis | 2 | $53 |
| Arcutis Biotherapeutics, Inc. | 2 | $49 |
| Botanix SB Inc | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $29 |
| LEO Pharma Inc. | 1 | $29 |
| Fresenius Kabi USA, LLC | 1 | $28 |
| Galderma Laboratories, L.p. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Dermavant Sciences, Inc. | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Strata Skin Sciences, Inc. | 1 | $18 |
How this compares
$654 in reported general payments places this provider in the 75th percentile of 2,320 family providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Taltz AutoinjectorIxekizumab | 20 | $160,993 |
| Azelaic Acid | 23 | $2,137 |
| Metronidazole | 32 | $1,667 |
| Fluorouracil | 26 | $1,510 |
| Clobetasol Propionate | 34 | $1,501 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 47 | $1,224 |
| CiclopiroxCiclopirox Olamine | 62 | $997 |
| Nystatin | 70 | $978 |
| Betamethasone Dipropionate | 17 | $825 |
| Doxycycline Hyclate | 38 | $615 |
| Spironolactone | 24 | $488 |
| Triamcinolone Acetonide | 63 | $454 |
| Ketoconazole | 31 | $379 |
| Clindamycin Phosphate | 16 | $375 |
| Ciclopirox | 11 | $284 |
Paid to pharmacies, not to this prescriber.
Other family in Concord
- Paul GouldLakeville$343K
- Brittany MurrayBoston$141K
- Courtney NixonAmherst$81K
- Elizabeth WalshBrighton$80K
- Jennifer FlemingLawrence$80K
- Naomi AmudalaBoston$79K
- Geoffrey WhitleyCharlestown$66K
- Katherine O'BrienWinthrop$58K
- Kristy SmithActon$57K
- Leslie StefanowiczDartmouth$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.